journal
https://read.qxmd.com/read/37980916/new-junk-food-legislation-in-colombia
#1
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
November 16, 2023: Lancet Oncology
https://read.qxmd.com/read/37977167/the-future-of-cancer-care-in-the-uk-time-for-a-radical-and-sustainable-national-cancer-plan
#2
REVIEW
Ajay Aggarwal, Ananya Choudhury, Nicola Fearnhead, Pam Kearns, Anna Kirby, Mark Lawler, Sarah Quinlan, Carlo Palmieri, Tom Roques, Richard Simcock, Fiona M Walter, Pat Price, Richard Sullivan
Cancer affects one in two people in the UK and the incidence is set to increase. The UK National Health Service is facing major workforce deficits and cancer services have struggled to recover after the COVID-19 pandemic, with waiting times for cancer care becoming the worst on record. There are severe and widening disparities across the country and survival rates remain unacceptably poor for many cancers. This is at a time when cancer care has become increasingly complex, specialised, and expensive. The current crisis has deep historic roots, and to be reversed, the scale of the challenge must be acknowledged and a fundamental reset is required...
November 14, 2023: Lancet Oncology
https://read.qxmd.com/read/37972608/development-and-validation-of-age-specific-risk-prediction-models-for-primary-ovarian-insufficiency-in-long-term-survivors-of-childhood-cancer-a-report-from-the-childhood-cancer-survivor-study-and-st-jude-lifetime-cohort
#3
JOURNAL ARTICLE
Cindy Im, Zhe Lu, Sogol Mostoufi-Moab, Angela Delaney, Lin Yu, Jessica L Baedke, Yutong Han, Yadav Sapkota, Yutaka Yasui, Eric J Chow, Rebecca M Howell, Smita Bhatia, Melissa M Hudson, Kirsten K Ness, Gregory T Armstrong, Paul C Nathan, Yan Yuan
BACKGROUND: Female survivors of childhood cancer are at risk for primary ovarian insufficiency (POI), defined as the cessation of gonadal function before the age of 40 years. We aimed to develop and validate models to predict age-specific POI risk among long-term survivors of childhood cancer. METHODS: To develop models to predict age-specific POI risk for the ages of 21-40 years, we used data from the Childhood Cancer Survivor Study (CCSS). Female survivors aged 18 years or older at their latest follow-up, with self-reported menstrual history information and free of subsequent malignant neoplasms within 5 years of diagnosis, were included...
November 13, 2023: Lancet Oncology
https://read.qxmd.com/read/37952543/cancer-care-in-nepal-after-earthquake
#4
JOURNAL ARTICLE
Manjulika Das
No abstract text is available yet for this article.
November 9, 2023: Lancet Oncology
https://read.qxmd.com/read/37952542/last-cancer-hospital-in-gaza
#5
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
November 9, 2023: Lancet Oncology
https://read.qxmd.com/read/37952541/optimising-follow-up-strategy-based-on-cytology-and-human-papillomavirus-after-fertility-sparing-surgery-for-early-stage-cervical-cancer-a-nationwide-population-based-retrospective-cohort-study
#6
JOURNAL ARTICLE
Teska N Schuurman, Mirte Schaafsma, Kaylee H To, Viola M J Verhoef, Karolina Sikorska, Albert G Siebers, Hans H B Wenzel, Maaike C G Bleeker, Eva Maria Roes, Ronald P Zweemer, Peggy J de Vos van Steenwijk, Refika Yigit, Jogchum J Beltman, Petra L M Zusterzeel, Christianne A R Lok, Ruud L M Bekkers, Constantijne H Mom, Nienke E van Trommel
BACKGROUND: The optimal follow-up strategy to detect recurrence after fertility-sparing surgery for early stage cervical cancer is unknown. Tailored surveillance based on individual risks could contribute to improved efficiency and, subsequently, reduce costs in health care. The aim of this study was to establish the predictive value of cervical cytology and high-risk human papillomavirus (HPV) testing to detect recurrent cervical intraepithelial neoplasia grade 2 or worse (CIN2+; including recurrent cervical cancer) after fertility-sparing surgery...
November 9, 2023: Lancet Oncology
https://read.qxmd.com/read/37951222/artificial-intelligence-based-pathology-as-a-biomarker-of-sensitivity-to-atezolizumab-bevacizumab-in-patients-with-hepatocellular-carcinoma-a-multicentre-retrospective-study
#7
JOURNAL ARTICLE
Qinghe Zeng, Christophe Klein, Stefano Caruso, Pascale Maille, Daniela S Allende, Beatriz Mínguez, Massimo Iavarone, Massih Ningarhari, Andrea Casadei-Gardini, Federica Pedica, Margherita Rimini, Riccardo Perbellini, Camille Boulagnon-Rombi, Alexandra Heurgué, Marco Maggioni, Mohamed Rela, Mukul Vij, Sylvain Baulande, Patricia Legoix, Sonia Lameiras, Léa Bruges, Viviane Gnemmi, Jean-Charles Nault, Claudia Campani, Hyungjin Rhee, Young Nyun Park, Mercedes Iñarrairaegui, Guillermo Garcia-Porrero, Josepmaria Argemi, Bruno Sangro, Antonio D'Alessio, Bernhard Scheiner, David James Pinato, Matthias Pinter, Valérie Paradis, Aurélie Beaufrère, Simon Peter, Lorenza Rimassa, Luca Di Tommaso, Arndt Vogel, Sophie Michalak, Jérôme Boursier, Nicolas Loménie, Marianne Ziol, Julien Calderaro
BACKGROUND: Clinical benefits of atezolizumab plus bevacizumab (atezolizumab-bevacizumab) are observed only in a subset of patients with hepatocellular carcinoma and the development of biomarkers is needed to improve therapeutic strategies. The atezolizumab-bevacizumab response signature (ABRS), assessed by molecular biology profiling techniques, has been shown to be associated with progression-free survival after treatment initiation. The primary objective of our study was to develop an artificial intelligence (AI) model able to estimate ABRS expression directly from histological slides, and to evaluate if model predictions were associated with progression-free survival...
November 8, 2023: Lancet Oncology
https://read.qxmd.com/read/37949087/an-hpv-vaccine-from-india-broadening-possibilities-for-cervical-cancer-control
#8
JOURNAL ARTICLE
John T Schiller, Aimée R Kreimer
No abstract text is available yet for this article.
November 7, 2023: Lancet Oncology
https://read.qxmd.com/read/37949086/immunogenicity-and-safety-of-a-new-quadrivalent-hpv-vaccine-in-girls-and-boys-aged-9-14-years-versus-an-established-quadrivalent-hpv-vaccine-in-women-aged-15-26-years-in-india-a-randomised-active-controlled-multicentre-phase-2-3-trial
#9
JOURNAL ARTICLE
Hitt Sharma, Sameer Parekh, Pramod Pujari, Sunil Shewale, Shivani Desai, Neerja Bhatla, Smita Joshi, Sharmila Pimple, Anand Kawade, Latha Balasubramani, Anitha Thomas, Vanita Suri, Sanjay Lalwani, Rajini Uday, Veena Kamath, Ranajit Mandal, A Rajeswar, Abraham Peedicayil, Usha Rani Poli, Dipanwita Banerjee, Rengaswamy Sankaranarayanan, Partha Basu, Richard Muwonge, Sunil Gairola, Vikas Dogar, Harish Rao, Umesh Shaligram
BACKGROUND: To meet global cervical cancer elimination efforts, a wider range of affordable and accessible vaccines against human papillomavirus (HPV) are needed. We aimed to evaluate the immunogenicity and safety of a quadrivalent HPV vaccine (targeting HPV types 6, 11, 16, and 18), developed and manufactured by the Serum Institute of India (SIIPL). Here we report outcomes in the 9-14 years cohort. METHODS: This randomised, active-controlled, phase 2/3 trial was conducted at 12 tertiary care hospitals across India...
November 7, 2023: Lancet Oncology
https://read.qxmd.com/read/37944542/performance-of-the-wid-qec-test-versus-sonography-to-detect-uterine-cancers-in-women-with-abnormal-uterine-bleeding-epi-sure-a-prospective-consecutive-observational-cohort-study-in-the-uk
#10
JOURNAL ARTICLE
Iona Evans, Daniel Reisel, Allison Jones, Alba Bajrami, Simrit Nijjar, Sarah Annie Solangon, Rupali Arora, Elisa Redl, Lena Schreiberhuber, Isma Ishaq-Parveen, Julia Rothärmel, Chiara Herzog, Davor Jurkovic, Martin Widschwendter
BACKGROUND: To detect uterine cancer, simpler and more specific index tests are needed to triage women with abnormal uterine bleeding to a reference histology test. We aimed to compare the performance of conventional index imaging tests with the novel WID-qEC DNA methylation test in terms of detecting the presence or absence of uterine cancers in women with abnormal uterine bleeding. METHODS: EPI-SURE was a prospective, observational study that invited all women aged 45 years and older with abnormal uterine bleeding attending a tertiary gynaecological diagnostic referral centre at University College London Hospital (London, UK) to participate...
November 6, 2023: Lancet Oncology
https://read.qxmd.com/read/37944541/fixed-duration-ibrutinib-venetoclax-versus-chlorambucil-obinutuzumab-in-previously-untreated-chronic-lymphocytic-leukaemia-glow-4-year-follow-up-from-a-multicentre-open-label-randomised-phase-3-trial
#11
JOURNAL ARTICLE
Carsten U Niemann, Talha Munir, Carol Moreno, Carolyn Owen, George A Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Tadeusz Robak, Martin Simkovic, Sergey Voloshin, Vladimir Vorobyev, Munci Yagci, Loic Ysebaert, Keqin Qi, Qianya Qi, Pierre Sinet, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Arnon P Kater
BACKGROUND: In the GLOW study, fixed-duration ibrutinib-venetoclax showed superior progression-free survival versus chlorambucil-obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbidities, or both, at a median follow up of 27·7 months. In this Article, we report updated outcomes from GLOW after a 46-month median follow-up. METHODS: GLOW was a randomised, multicentre, phase 3 study done at 67 hospital centres across 14 countries...
November 6, 2023: Lancet Oncology
https://read.qxmd.com/read/37944540/long-term-efficacy-of-ibrutinib-venetoclax-for-first-line-treatment-in-chronic-lymphocytic-leukaemia
#12
JOURNAL ARTICLE
Anna Fink
No abstract text is available yet for this article.
November 6, 2023: Lancet Oncology
https://read.qxmd.com/read/37944539/non-invasive-dna-methylation-based-testing-for-the-diagnosis-of-endometrial-cancer
#13
JOURNAL ARTICLE
Jessica St Laurent, Kevin M Elias
No abstract text is available yet for this article.
November 6, 2023: Lancet Oncology
https://read.qxmd.com/read/37931625/hpv-vaccine-roll-out-in-nigeria-and-bangladesh
#14
JOURNAL ARTICLE
Munyaradzi Makoni
No abstract text is available yet for this article.
November 3, 2023: Lancet Oncology
https://read.qxmd.com/read/37926102/iaslc-calls-for-clinical-trials-to-use-tobacco-use-data
#15
JOURNAL ARTICLE
Bryant Furlow
No abstract text is available yet for this article.
November 2, 2023: Lancet Oncology
https://read.qxmd.com/read/37926101/proposal-to-lower-australia-s-bowel-screening-age-limit-from-50-to-45-years
#16
JOURNAL ARTICLE
Tony Kirby
No abstract text is available yet for this article.
November 2, 2023: Lancet Oncology
https://read.qxmd.com/read/37926100/accelerated-versus-standard-epirubicin-followed-by-cyclophosphamide-methotrexate-and-fluorouracil-or-capecitabine-as-adjuvant-therapy-for-breast-cancer-uk-tact2-cruk-05-19-quality-of-life-results-from-a-multicentre-phase-3-open-label-randomised-controlled-trial
#17
JOURNAL ARTICLE
Galina Velikova, James P Morden, Joanne S Haviland, Charlotte Emery, Peter Barrett-Lee, Helena Earl, David Bloomfield, Adrian Murray Brunt, Peter Canney, Robert Coleman, Mark Verrill, Andrew Wardley, Gianfilippo Bertelli, Paul Ellis, Rob Stein, Judith M Bliss, David Cameron
BACKGROUND: Adjuvant chemotherapy for patients with early breast cancer improves outcomes but its toxicity affects patients' quality of life (QOL). The UK TACT2 trial investigated whether accelerated epirubicin improves time to recurrence and if oral capecitabine is non-inferior to cyclophosphamide, methotrexate, and fluorouracil (CMF) for efficacy with less toxicity. Results showed no benefit for accelerated epirubicin and capecitabine was non-inferior. As part of the QOL substudy, we aimed to assess the effect of chemotherapies on psychological distress, physical symptoms, and functional domains...
November 2, 2023: Lancet Oncology
https://read.qxmd.com/read/37924824/improving-access-to-surgery-for-childhood-cancer
#18
JOURNAL ARTICLE
Lars Hagander
No abstract text is available yet for this article.
November 1, 2023: Lancet Oncology
https://read.qxmd.com/read/37924823/global-cancer-surgery-a-vital-service-to-eliminate-false-economy
#19
JOURNAL ARTICLE
Allison Landman, David Collingridge
No abstract text is available yet for this article.
November 1, 2023: Lancet Oncology
https://read.qxmd.com/read/37924822/cancer-surgery-orchestrating-cancer-control-by-strengthening-health-systems
#20
JOURNAL ARTICLE
Mary Gospodarowicz, Anna Dare, David A Jaffray
No abstract text is available yet for this article.
November 1, 2023: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.